Epilepsy, Partial Clinical Trial
Official title:
A 19-week, Randomized, Double-blind, Multicenter, Placebo-controlled Safety Study to Evaluate the Cognitive and Neuropsychological Effects of Levetiracetam 20 - 60 mg/kg/Day, Divided in Twice Daily Dosing, as Adjunctive Treatment in Children 4 - 16 Years Old, Inclusive, With Refractory Partial Onset Seizures
A 12-week Evaluation Period will be used to characterize potential cognitive and neuropsychological effects of LEV (20 - 60 mg/kg/day), as adjunctive treatment in children 4 - 16 years old, inclusive, with refractory partial onset seizures when compared to adjunctive treatment with placebo.
n/a
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00160615 -
Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label Method
|
Phase 3 | |
Completed |
NCT00175890 -
A Placebo-controlled Study of Levetiracetam In Children (1mo to 4yrs of Age) With Partial Onset Seizures.
|
Phase 3 | |
Completed |
NCT00152516 -
Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures
|
Phase 3 | |
Completed |
NCT00113165 -
Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Partial Seizures
|
Phase 3 | |
Withdrawn |
NCT01691872 -
Pharmacokinetic Study of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects
|
Phase 1 | |
Completed |
NCT00160654 -
Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy
|
Phase 4 | |
Terminated |
NCT01545518 -
IVIG Treatment for Refractory Immune-Related Adult Epilepsy
|
Phase 2 | |
Completed |
NCT00141414 -
To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.
|
Phase 2 | |
Completed |
NCT01332539 -
An Observational Study to Assess the Burden of Drug-resistant Partial Epilepsy in Italy
|
N/A | |
Completed |
NCT00355082 -
Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy
|
Phase 3 | |
Completed |
NCT00152451 -
Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures
|
Phase 2 | |
Withdrawn |
NCT02220972 -
To Evaluate the Effect of Perampanel on Objective and Subjective Sleep in Subjects With Insomnia and Partial Onset Seizures
|
Phase 4 | |
Completed |
NCT00160628 -
Open Label Safety and Efficacy Study of Levetiracetam in Korean Patients With Epilepsy
|
Phase 3 | |
Completed |
NCT00245713 -
Determine Effects of Adjunctive Levetiracetam on Sleep Architecture in Adults With Partial Onset Epilepsy.
|
Phase 4 | |
Terminated |
NCT01375374 -
Hormonal and Lipid Levels in Male Subjects After a Switch From Carbamazepine to Lacosamide
|
Phase 3 | |
Completed |
NCT00152373 -
Double-blind, Placebo-controlled Study of Levetiracetam in Adults With POS
|
Phase 3 | |
Completed |
NCT00150709 -
A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With Epilepsy
|
Phase 3 | |
Completed |
NCT00643500 -
Pharmacovigilance Study of Keppra. SPAIN - SKATE : Safety of Keppra as Adjunctive Therapy in Epilepsy
|
Phase 4 | |
Completed |
NCT00152503 -
Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam
|
Phase 2 | |
Terminated |
NCT01891890 -
Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)
|
Phase 3 |